Carl Zeiss Meditec (OTCMKTS:CZMWY) Upgraded at Zacks Research

Zacks Research upgraded shares of Carl Zeiss Meditec (OTCMKTS:CZMWY) from a strong sell rating to a hold rating in a research note published on Tuesday,Zacks reports.

A number of other brokerages also recently issued reports on CZMWY. Morgan Stanley began coverage on Carl Zeiss Meditec in a report on Wednesday, September 2nd. They issued an “underweight” rating on the stock. The Goldman Sachs Group cut Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a research note on Monday. Finally, UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Carl Zeiss Meditec currently has a consensus rating of “Strong Sell”.

Carl Zeiss Meditec Price Performance

Shares of OTCMKTS:CZMWY opened at $34.98 on Tuesday. The firm has a 50 day moving average of $35.74 and a 200 day moving average of $32.51. Carl Zeiss Meditec has a 52 week low of $26.65 and a 52 week high of $55.94.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a Germany-based medical technology company focused on ophthalmology and microsurgery. The company develops, manufactures and distributes diagnostic and therapeutic systems, surgical equipment, implants and related digital solutions for healthcare professionals.

Its ophthalmic portfolio includes devices for eye examinations and diagnostics, laser systems for refractive and cataract procedures, surgical microscopes, intraocular lenses and other products used in cataract, retinal, glaucoma and corneal treatments.